Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel

Introduction: Conventional anti-androgen regimens were widely used as an initiation or combined androgen blockade (CAB) therapy in advanced prostate cancer patients. Currently, new androgen pathway inhibitors such as abiraterone acetate (AA) and enzalutamide had been proven effective in metastatic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian-Ri, Chiu, Kun-Yuan, Wang, Shian-Shiang, Yang, Cheng-Kuang, Chen, Chuan-Shu, Ho, Hao-Chung, Hung, Chi-Feng, Cheng, Chen-Li, Yang, Chi-Rei, Chen, Cheng-Che, Wang, Shu-Chi, Lin, Chia-Yen, Chang, Chao-Hsiang, Hsu, Chiann-Yi, Ou, Yen-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702804/
https://www.ncbi.nlm.nih.gov/pubmed/29213237
http://dx.doi.org/10.3389/fphar.2017.00836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702804/
https://www.ncbi.nlm.nih.gov/pubmed/29213237
http://dx.doi.org/10.3389/fphar.2017.00836

Ejemplares similares